Literature DB >> 21218538

Aliskiren as an add-on treatment reduces albuminuria in patients with diabetes.

Susan J Allison.   

Abstract

Entities:  

Year:  2011        PMID： 21218538     DOI： 10.1038/nrneph.2010.165

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  3 in total

1.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  Nephrol Dial Transplant       Date:  2009-01-14       Impact factor: 5.992

2.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

3.  Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Authors:  Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2010-08-06       Impact factor: 17.152
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.